Can AI Tools, $76M Lead BlackThorn to Targeted Pysch Drugs?
Xconomy
JUNE 13, 2019
The new Series B round will give San Francisco-based BlackThorn—a startup spun out of the Scripps Research Institute in 2013—the backing to run human tests of two experimental treatments. The other, for autism, could start a Phase 1 study in 2020. Those plans.
Let's personalize your content